Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia

Blood

Volumn 95, Issue 3, 2000, Pages 738-744

  Sinclair, P B ^b   Nacheva, E P ^b   Leversha, M ^b   Telford, N ^b   Chang, J ^b   Reid, A ^b   Bench, A ^b   Champion, K ^b   Huntly, B ^b   Green, A R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CHROMOSOMAL LOCALIZATION; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; FUSION GENE; GENE TRANSLOCATION; HUMAN; IN SITU HYBRIDIZATION; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 12944295358     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.738.003k21_738_743     Document Type: Article

References (53)

1. Goldman JM. Chronic myeloid leukemia. Curr Opin Hematol. 1997;4:277-285.
2. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996; 1000:555-570.
3. Enright H, McGlave PB. Chronic myelogenous leukemia. Curr Opin Hematol. 1996;3:303-309.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
5. Elefanty AG, Hariharan IK, Cory S. BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
6. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
7. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A. 1993;90:3755-3759.
8. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interteukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92:3829-3840.
9. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.
10. Gribble SM, Sinclair PB, Grace C, Green AR, Nacheva EP. Comparative analysis of G banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet. 1999;111: 7-17.
11. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013-2016.
12. Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1995;91:625-629.
13. Stuppia L, Calabrese G, Peila R, et al. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis. Cancer Genet Cytogenet. 1997;98:28-35.
14. Serra A, Guerrasio A, Gaidano G, et al. Molecular defects associated with the acute phase CML. Leuk Lymphoma. 1993;11:25-28.
15. Mori N, Morosetti R, Lee S, et al. Allelotype analysis in the evolution of chronic myelocytic leukemia Blood. 1997;90:2010-2014.
16. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
17. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
18. Mills KI, MacKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood. 1988;72:1237-1241.
19. Martinelli G, Chiamenti A, Gasparini P, et al. BCR breakpoint subregions and blast crisis lineage in CML patients. Blood. 1992;79:838-839.
20. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546-554.
21. Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia. 1995;9:1104-1107.
22. Fioretos T, Nilsson PG, Aman P, et al. Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. Leukemia. 1993;7:1225-1231.
23. Melo JV, Gordon DE, Tuszynski A, et al. Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. Blood. 1993;81:2488-2491.
24. Melo JV, Hochhaus A, Yan XH, Goldman JM. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol. 1996;92:684-686.
25. Chissos SL, Bodenteich A, Wang YF, et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics. 1995;27:67-82.
26. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood. 1997;90:1395-1402.
27. Collins JE, Cole CG, Smink LJ, et al. A high-density YAC contig map of human chromosome 22. Nature. 1995;377:367-379.
28. Povey S, Armour J, Farndon P, et al. Report on the Third International Workshop on Chromosome 9. Ann Hum Genet. 1994;58:177-250.
29. Nacheva E, Holloway T, Brown K, Bloxham D, Green AR. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol. 1994;87:409-412.
30. Nacheva E, Grace C, Holloway TL, Green AR. Comparative genomic hybridization in acute myeloid leukaemia: a comparison with G-banding and chromosome painting. Cancer Genet Cytogenet. 1995;82:9-16.
31. Asimakopoulos FA, Holloway TL, Nacheva EP, Scott MA, Fenaux P, Green AR. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood. 1996;87:1561-1570.
32. Yuille MA, Hampson RM, Harris RM, Affara NA, Yates JR, Ferguson-Smith MA. CA repeat polymorphism at the ASS locus. Nucleic Acids Res. 1990;18:7472.
33. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-1397.
34. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-825.
35. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
36. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064-4077.
37. Shimizu K, Miyoshi H, Kozu T, et al. Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation. Cancer Res. 1992;52:6945-6948.
38. Liu P, Siciliano J, Seong D, et al. Dual Alu polymerase chain reaction primers and conditions for isolation of human chromosome painting probes from hybrid cells. Cancer Genet Cytogenet. 1993; 65:93-99.
39. Dauwerse JG, Wessels JW, Giles RH, et al. Cloning the breakpoint cluster region of the inv(16) in acute nonlymphocytic leukemia M4 Eo. Hum Mol Genet. 1993;2:1527-1534.
40. Kuss BJ, Deeley RG, Cole SP, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet. 1994;343:1531-1534.
41. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood. 1995;85:772-779.
42. Corral J, Forster A, Thompson S, et al. Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. Proc Natl Acad Sci USA. 1993;90:8538-8542.
43. Popenoe DW, Schaefer-Rego K, Mears JG, Bank A, Leibowitz D. Frequent and extensive deletion during the 9,22 translocation in CML. Blood. 1986;68:1123-1128.
44. Shtalrid M, Talpaz M, Kurzrock R, et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood. 1988; 72:485-490.
45. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol. 1996;95:219-226.
46. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700-9704.
47. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med. 1995;1:686-692.
48. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998; 396:177-180.
49. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
50. Petrij F, Giles RH, Dauwerse HG, et al. Rubenstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 1995; 376:348-352.
51. Scherer SS, Chance PF. Myelin genes: getting the dosage right. Nat Genet. 1995;11:226-228.
52. Hartl DL. The most unkindest cut of all. Nat Genet. 1996;12:277-279.
53. Fisher E, Scambler P. Human haploinsufficiency - one for sorrow, two for joy. Nat Genet. 1994;7:5-7.